HC Wainwright Predicts Valneva’s Q2 Earnings (NASDAQ:VALN)

Valneva SE Sponsored ADR (NASDAQ:VALN) – Equities researchers at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for Valneva in a research report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.28) for the quarter, down from their prior forecast of ($0.21). The consensus estimate for Valneva’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Valneva’s Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.89 EPS, FY2028 earnings at $2.22 EPS, FY2029 earnings at $2.38 EPS and FY2030 earnings at $4.13 EPS.

Other analysts have also recently issued research reports about the company. Guggenheim set a $11.00 price objective on Valneva in a research report on Thursday, April 16th. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, The Goldman Sachs Group downgraded Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $11.98.

Valneva Trading Up 0.5%

Valneva stock opened at $5.71 on Tuesday. The stock has a market cap of $541.82 million, a PE ratio of -3.05 and a beta of 1.72. The stock has a 50-day moving average price of $6.98 and a 200 day moving average price of $8.56. Valneva has a 52 week low of $5.06 and a 52 week high of $12.25. The company has a current ratio of 2.14, a quick ratio of 1.60 and a debt-to-equity ratio of 2.14.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The firm had revenue of $35.77 million during the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%.

Institutional Trading of Valneva

A number of institutional investors have recently modified their holdings of the company. Marex Group plc purchased a new stake in shares of Valneva during the 2nd quarter worth about $64,000. XTX Topco Ltd purchased a new stake in shares of Valneva during the 4th quarter worth about $94,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the 3rd quarter worth about $124,000. VSM Wealth Advisory LLC grew its holdings in shares of Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva during the 4th quarter worth about $44,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.